The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease

Autor:	Sabita S. Soedamah-Muthu, Mike Mackness, J. H. Fuller, M J Thomason, D. J. Betteridge, H. A. W. Neil, P.N. Durrington, K. Julier, Graham A. Hitman, Helen M. Colhoun
Jazyk:	angličtina
Rok vydání:	2016
Předmět:	Male Very low-density lipoprotein Magnetic Resonance Spectroscopy coronary-artery-disease Apolipoprotein B Nutrition and Disease Atorvastatin Myocardial Ischemia Blood lipids Lipoproteins VLDL chemistry.chemical_compound Reference Values Voeding en Ziekte Hyperlipidemia simvastatin treatment biology b-containing lipoproteins Middle Aged cholesteryl ester transfer Lipoproteins LDL coa reductase inhibitor Treatment Outcome triglyceride-rich lipoproteins Female lipids (amino acids peptides and proteins) Lipoproteins HDL Cardiology and Cardiovascular Medicine medicine.drug medicine.medical_specialty Statin pravastatin treatment medicine.drug_class Hyperlipidemias Risk Assessment Double-Blind Method Internal medicine medicine low-density lipoproteins Humans Pyrroles cardiovascular diseases Aged Probability VLAG Triglyceride business.industry nutritional and metabolic diseases medicine.disease familial combined hyperlipidemia Endocrinology Diabetes Mellitus Type 2 chemistry Heptanoic Acids biology.protein Patient Compliance subfraction Hydroxymethylglutaryl-CoA Reductase Inhibitors business Lipoprotein
Zdroj:	Atherosclerosis 167 (2003) 2 Atherosclerosis, 167(2), 243-255
ISSN:	0021-9150
DOI:	10.1016/s0021-9150(02)00428-8
Popis:	The effect of statin therapy on subclasses of LDL, VLDL and HDL lipoproteins is unclear. We compared changes in serum lipids, apolipoproteins and nuclear magnetic resonance (NMR) spectroscopy measured lipoprotein subclass concentration and average particle size over a minimum 6 months treatment period of atorvastatin 10 mg vs. placebo in 122 men and women. All subjects had type 2 diabetes and a modest dyslipidaemia (mean LDL-cholesterol 3.2 mmol/l and median triglycerides 1.8 mmol/l) and had a previous myocardial infarction. Compared with placebo, atorvastatin therapy was associated with a greater decrease in medium VLDL (median within person change -13.4 vs. -5.9 nmol/l, P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ca39aac9cfc1f7cba27561c5736264c https://doi.org/10.1016/s0021-9150(02)00428-8 Zobrazit plný text záznamu Full Text from ScienceDirect